Twitter

Link your Twitter Account to Market Wire News


When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.


Be alerted of any news about your stocks and see what other stocks are trending.



home / articles / MMSI - Merit Medical Reports Results for First Quarter Ended March 31 2024 | Benzinga


MMSI - Merit Medical Reports Results for First Quarter Ended March 31 2024 | Benzinga

    • Q1 2024 reported revenue of $323.5 million, up 8.7% compared to Q1 2023
    • Q1 2024 constant currency revenue* up 9.3% compared to Q1 2023
    • Q1 2024 constant currency revenue, organic* up 7.0% compared to Q1 2023
    • Q1 2024 GAAP operating margin of 11.1%, compared to 8.9% in Q1 2023
    • Q1 2024 non-GAAP operating margin* of 17.3%, compared to 16.1% in Q1 2023
    • Q1 2024 GAAP EPS $0.48, up 35.5%, compared to $0.36 in Q1 2023
    • Q1 2024 non-GAAP EPS* $0.77, up 18.7%, compared to $0.64 in Q1 2023

    * Constant currency revenue; constant currency revenue, organic; non-GAAP gross profit and margin; non-GAAP operating income and margin; non-GAAP net income; non-GAAP EPS; and free cash flow are non-GAAP financial measures. A reconciliation of these financial measures to their most directly comparable GAAP financial measures is included under the heading "Non-GAAP Financial Measures" below.

    SOUTH JORDAN, Utah, April 30, 2024 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ:MMSI), a leading global manufacturer and marketer of healthcare technology, today announced revenue of $323.5 million for the quarter ended March 31, 2024, an increase of 8.7% compared to the quarter ended March 31, 2023. Constant currency revenue, organic, for the first quarter of 2024 increased 7.0% compared to the prior year period.

    Merit's revenue by operating segment and product category for the three-month periods ended March 31, 2024 and 2023 was as follows (unaudited; in thousands, except for percentages):

     
    Three Months Ended
     
    Reported
     
     
     
     
    Constant Currency *
     
    March 31,
     
     
     
     
    Impact of foreign
     
    March 31,
     
     
     
     
    2024
     
    2023
     
    % Change
     
    exchange
     
    2024
     
    % Change
    Cardiovascular
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
    Peripheral Intervention
    $
    134,626
     
    $
    113,783
     
    18.3
     
    %
     
    $
    367
     
     
    $
    134,993
     
    18.6
     
    %
    Cardiac Intervention
     
    90,688
     
     
    85,328
     
    6.3
     
    %
     
     
    932
     
     
     
    91,620
     
    7.4
     
    %
    Custom Procedural Solutions
     
    48,794
     
     
    47,701
     
    2.3
     
    %
     
     
    403
     
     
     
    49,197
     
    3.1
     
    %
    OEM
     
    39,266
     
     
    41,164
     
    (4.6
    )
    %
     
     
    (37
    )
     
     
    39,229
     
    (4.7
    )
    %
    Total
     
    313,374
     
     
    287,976
     
    8.8
     
    %
     
     
    1,665
     
     
     
    315,039
     
    9.4
     
    %
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
    Endoscopy
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
    Endoscopy Devices
     
    10,134
     
     
    9,589
     
    5.7
     
    %
     
     
    27
     
     
     
    10,161
     
    6.0
     
    %
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
    Total
    $
    323,508
     
    $
    297,565
     
    8.7
     
    %
     
    $
    1,692
     
     
    $
    325,200
     
    9.3
     
    %
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     

    Merit's GAAP gross margin for the first quarter of 2024 was 46.9%, compared to GAAP gross margin of 46.5% for the prior year period. Merit's non-GAAP gross margin* for the first quarter of 2024 was 50.9%, compared to non-GAAP gross margin* of 50.1% for the first quarter of 2023.

    Merit's GAAP net income for the first quarter of 2024 was $28.2 million, or $0.48 per share, compared to GAAP net income of $20.7 million, or $0.36 per share, for the first quarter of 2023. Merit's non-GAAP net income* for the first quarter of 2024 was $44.8 million, or $0.77 per share, compared to non-GAAP net income* of $37.5 million, or $0.64 per share, for the first quarter of 2023.

    "We delivered better-than-expected revenue and financial results in the first quarter," said Fred P. Lampropoulos, Merit's Chairman and Chief Executive Officer. "Our constant currency, organic, revenue increased 7.0% year-over-year and our constant currency total revenue increased 9.3%, both of which exceeded the high-end of our expectations. We also delivered year-over-year improvement in profitability with our non-GAAP gross and operating margins increasing 80 bps and 115 bps, respectively, and our non-GAAP earnings per share increasing 19% year-over-year. This strong growth and profitability performance drove free cash flow generation of approximately $25 million of in the quarter as well. We are pleased with the solid start to the fiscal year and remain confident in our team's ability to deliver continued strong execution, stable constant currency growth, improving profitability and solid free cash flow generation in 2024."

    As of March 31, 2024, Merit had cash and cash equivalents of $581.9 million, total debt obligations of $822.5 million, and available borrowing capacity of approximately $657 million, compared to cash and cash equivalents of $587 million, total debt obligations of $846.6 million, and available borrowing capacity of approximately $626 million as of December 31, 2023.

    Reaffirmed Fiscal Year 2024 Financial Guidance

    Based upon the information currently available to Merit's management, for the year ending December 31, 2024, absent material acquisitions, non-recurring transactions or other factors beyond Merit's current expectations, Merit continues to expect the following:

    Revenue and Earnings Guidance*

     
     
    Guidance
     
     
    Year Ending
    % Change
    Financial Measure
     
    December 31, 2024
    Y/Y
     
     
     
     
    Net Sales
     
    $1.312 - $1.325 billion
    4% - 5%
    Cardiovascular Segment
     
    $1.272 - $1.285 billion
    4% - 5%
    Endoscopy Segment
     
    $39.7 - $40.1 million
    8% - 9%
     
     
     
     
    Non-GAAP
     
     
     
    Earnings Per Share
     
    $3.28 - $3.35
    9% - 11%
     
     
     
     

    *Percentage figures approximated; dollar figures may not foot due to rounding

    2024 Net Sales Guidance - % Change from Prior Year (Constant Currency) Reconciliation*

     
     
     
     
     
    Guidance
     
    Low
     
    High
    2024 Net Sales Guidance - % Change from Prior Year (GAAP)
    4.3%
     
    5.4%
    Estimated impact of foreign currency exchange rate fluctuations
    0.5%
     
    0.5%
    2024 Net Sales Guidance - % Change from Prior Year (Constant Currency)
    4.8%
     
    5.9%
     
     
     
     

    *Percentage figures approximated and may not foot due to rounding

    Merit does not provide guidance for GAAP reported financial measures (other than revenue) or a reconciliation of forward-looking non-GAAP financial measures to the most directly comparable GAAP reported financial measures (other than revenue) because Merit is unable to predict with reasonable certainty the financial impact of items such as expenses related to acquisitions or other extraordinary transactions, non-cash expenses related to amortization or write-off of previously acquired tangible and intangible assets, certain severance expenses, performance-based stock compensation expenses, corporate transformation expenses, expenses resulting from non-ordinary course litigation or administrative proceedings and resulting settlements, governmental proceedings, and changes in governmental or industry regulations. These items are uncertain, depend on various factors, and could have a material impact on GAAP reported results for the guidance period. For the same reasons, Merit is unable to address the significance of the unavailable information, which could be material to future results. Specifically, Merit is not, without unreasonable effort, able to reliably predict the impact of these items and Merit believes inclusion of a reconciliation of these forward-looking non-GAAP measures to their GAAP counterparts could be confusing to investors or cause undue reliance.

    Merit's financial guidance for the year ending December 31, 2024 is subject to risks and uncertainties identified in this release and Merit's filings with the U.S. Securities and Exchange Commission (the "SEC").

    CONFERENCE CALL

    Merit will hold its investor conference call today, Tuesday, April 30, 2024, at 5:00 p.m. Eastern (4:00 p.m. Central, 3:00 p.m. Mountain, and 2:00 p.m. Pacific). To access the conference call, please pre-register using the following link. Registrants will receive confirmation with dial-in details. A live webcast and slide deck will also be available at merit.com.

    CONSOLIDATED BALANCE SHEETS
    (in thousands)
     
     
     
     
     
     
     
    March 31,
     
     
     
     
    2024
     
    December 31,
     
    (Unaudited)
     
    2023
    ASSETS
     
     
     
     
     
    Current Assets
     
     
     
     
     
    Cash and cash equivalents
    $
    581,921
     
     
    $
    587,036
     
    Trade receivables, net
     
    180,663
     
     
     
    177,885
     
    Other receivables
     
    10,980
     
     
     
    10,517
     
    Inventories
     
    302,733
     
     
     
    303,871
     
    Prepaid expenses and other assets
     
    24,437
     
     
     
    24,286
     
    Prepaid income taxes
     
    4,088
     
     
     
    4,016
     
    Income tax refund receivables
     
    453
     
     
     
    859
     
    Total current assets
     
    1,105,275
     
     
     
    1,108,470
     
     
     
     
     
     
     
    Property and equipment, net
     
    383,661
     
     
     
    383,523
     
    Intangible assets, net
     
    317,484
     
     
     
    325,883
     
    Goodwill
     
    381,539
     
     
     
    382,240
     
    Deferred income tax assets
     
    7,072
     
     
     
    7,288
     
    Operating lease right-of-use assets
     
    72,639
     
     
     
    63,047
     
    Other assets
     
    58,682
     
     
     
    54,793
     
    Total Assets
    $
    2,326,352
     
     
    $
    2,325,244
     
     
     
     
     
     
     
    LIABILITIES AND STOCKHOLDERS' EQUITY
     
     
     
     
     
    Current Liabilities
     
     
     
     
     
    Trade payables
    $
    48,377
     
     
    $
    65,944
     
    Accrued expenses
     
    113,220
     
     
     
    120,447
     
    Current operating lease liabilities
     
    12,472
     
     
     
    12,087
     
    Income taxes payable
     
    9,275
     
     
     
    5,086
     
    Total current liabilities
     
    183,344
     
     
     
    203,564
     
     
     
     
     
     
     
    Long-term debt
     
    800,136
     
     
     
    823,013
     
    Deferred income tax liabilities
     
    5,519
     
     
     
    5,547
     
    Long-term income taxes payable
     
    347
     
     
     
    347
     
    Liabilities related to unrecognized tax benefits
     
    1,912
     
     
     
    1,912
     
    Deferred compensation payable
     
    18,228
     
     
     
    17,167
     
    Deferred credits
     
    1,579
     
     
     
    1,605
     
    Long-term operating lease liabilities
     
    60,141
     
     
     
    56,259
     
    Other long-term obligations
     
    14,956
     
     
     
    13,830
     
    Total liabilities
     
    1,086,162
     
     
     
    1,123,244

    Full story available on Benzinga.com

  • Stock Information

    Company Name: Merit Medical Systems Inc.
    Stock Symbol: MMSI
    Market: NASDAQ
    Website: merit.com

    Menu

    MMSI MMSI Quote MMSI Short MMSI News MMSI Articles MMSI Message Board
    Get MMSI Alerts

    News, Short Squeeze, Breakout and More Instantly...